Identification of Degradation Products and a Stability-Indicating RP-HPLC Method for the Determination of Belzutifan in Pharmaceutical Dosage Forms
Authors:
Open Access
- 1 July 2025
- journal article
- Published by Wolters Kluwer Health in Journal of Pharmacy and Bioallied Sciences
- Vol. 17 (3) , 134-139
Abstract
Background: Hypoxia-inducible factor-2alpha (HIF-2α) is a protein, the selective inhibitor of which (belzutifan) is used in the treatment of cancers related to von Hippel-Lindau (VHL) disease. No analytical procedure has been so far reported in the identification of forced degradation products of belzutifan. Thus, the current project was conducted to design and approve the liquid chromatography-mass spectrometry/mass spectrometry (LC-MS/MS) technique to perform a full analysis of it. Objective: This research was to develop and confirm a strong high-performance liquid chromatography (HPLC) procedure in the quantification of belzutifan in the tablet dosage form and to utilize LC-MS/MS in the characterization of the forced degradation products of belzutifan. Approach: The separation was done by the chromatographic method utilizing a Zorbax C 18 column with the mobile phase comprised of acetonitrile and 0.1% formic acid (50:50, v/v), and the flow rate was 1.0 mL/min with 247nm as a detector wavelength. Belzutifan had a retention time of 2.338 min and a total reaction time of 4 min. Results: The derived technique showed great linearity (R2 > 0.999) in the range of concentrations (10-60 μg/ml) and good accuracy, precision, and strength. The forced degradation analysis identified specific degradation products, which were further identified using the LC-MS/MS, thus gathering significant information about the stability profile of belzutifan in stressful environments. Conclusion: This study developed and validated a simple, rapid, cost-effective, and highly sensitive RP-HPLC method for quantitative estimation of belzutifan in tablets. The method complied with ICH guidelines, demonstrating excellent linearity, accuracy, specificity, robustness, and stability. Linearity was achieved over a wide range, with no interference from excipients, confirming its reliability. Relative standard deviations (RSD) were below 2%, indicating precision and reproducibility. Owing to its simplicity and efficiency, the method is suitable for routine quality control in pharmaceutical laboratories.Keywords
This publication has 15 references indexed in Scilit:
- Development and Validation of the Ultra-Performance Liquid Chromatography Method for Quantification of Belzutifan in Pharmaceutical Dosage FormPharmaceutical Chemistry Journal, 2024
- Development and Validation of a High Throughput Lc-Ms/Ms Method for Quantitation of Ipilimumab in Human PlasmaInternational Journal of Pharmaceutical Quality Assurance, 2022
- FDA Approval Summary: Belzutifan for von Hippel-Lindau Disease–Associated TumorsClinical Cancer Research, 2022
- A Validated RP-HPLC Method for the Simultaneous Detection and Quantification of Pyridoxine and Terizidone in Pharmaceutical FormulationsAnalytica, 2021
- Belzutifan for Renal Cell Carcinoma in von Hippel–Lindau DiseaseNew England Journal of Medicine, 2021
- Belzutifan, a Potent HIF2α Inhibitor, in the Pacak–Zhuang SyndromeNew England Journal of Medicine, 2021
- STABILITY INDICATING AND COST-EFFECTIVE ANALYTICAL METHOD DEVELOPMENT AND VALIDATION OF SOTORASIB BY USING RP-HPLCInternational Journal of Applied Pharmaceutics, 2021
- Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysisNature Medicine, 2021
- Development and validation of RP-HPLC method for simultaneous determination of lamivudine, stavudine, and zidovudine in perfusate samples: Application to the Single-Pass Intestinal Perfusion (SPIP) studiesBrazilian Journal of Pharmaceutical Sciences, 2021
- Validated HPLC‐MS/MS method for quantitation of AMG 510, a KRAS G12C inhibitor, in mouse plasma and its application to a pharmacokinetic study in miceBiomedical Chromatography, 2020